Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

Neurology
C T BeverK P Johnson

Abstract

To examine the efficacy and toxicity of oral 3,4 diaminopyridine (DAP) in dosages up to 100 mg/day, 36 patients with multiple sclerosis (MS) enrolled in a randomized, double-blind, placebo-controlled, crossover trial. The primary outcome measure was improvement of a prospectively defined neurologic deficit, which was leg weakness in 34 patients. Secondary outcome measures included the patient's subjective response, scored manual motor testing (MMT) of leg strength, scored leg strength from videotaped motor testing (VMT), quadriceps and hamstrings strength (QMT) measured by isometric dynamometry, neuropsychological testing (NPT), ambulation index (AI), and Expanded Disability Status Scale (EDSS) score. Paresthesias and abdominal pain were common and were dose limiting in eight patients. Three patients had episodes of confusion, and one patient had a seizure while on DAP. Eight patients withdrew from the study, leaving 28 evaluable patients for the efficacy analysis. The prospectively defined neurologic deficit improved in 24 patients-22 on DAP and 2 on placebo (p = 0.0005). All improvements were in leg weakness. Subjective response and measures of leg strength and function (MMT, VMT, QMT, and AI) improved on DAP compared with pl...Continue Reading

Citations

Nov 28, 2012·Journal of Neurology·Maria Pia AmatoGiancarlo Comi
Nov 30, 2000·Current Treatment Options in Neurology·C T Bever
Nov 28, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew D Goodman, Robert Thompson Stone
Aug 15, 2002·International Journal of Pharmaceutics·Stéphane GibaudAlain Astier
Nov 11, 1999·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·L M MetzD McGowan
May 11, 2011·Nature Reviews. Neurology·Ralph H B Benedict, Robert Zivadinov
Apr 29, 1998·BMJ : British Medical Journal·M R Rose
Jun 23, 2011·Therapeutic Advances in Neurological Disorders·João Carlos Correia de SaBernd C Kieseier
Mar 13, 2014·Archives of Physical Medicine and Rehabilitation·Meghan BeierGeorge H Kraft
Sep 2, 1998·Current Opinion in Neurology·A J Thompson
Oct 29, 2010·Expert Review of Clinical Immunology·Paul W WirtzJan J Verschuuren
Nov 1, 2002·Expert Review of Neurotherapeutics·Giancarlo Comi, Leitizia Leocani
Nov 3, 2006·Expert Review of Neurotherapeutics·Stephanie H Ameis, Anthony Feinstein
Oct 22, 2008·Expert Review of Neurotherapeutics·Maria Pia AmatoEmilio Portaccio
Jun 30, 2006·Expert Opinion on Pharmacotherapy·Jan J G M VerschuurenJoop van Gerven
Jan 27, 2010·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Steve VucicMatthew C Kiernan
Apr 14, 2009·Revue neurologique·M DebouverieF Guillemin
Jun 19, 2007·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Delphine BoërioJean-Pascal Lefaucheur
Apr 29, 2006·Journal of the Neurological Sciences·Maria Pia AmatoValentina Zipoli
Feb 14, 2006·Pharmacology & Therapeutics·Susan I V Judge, Christopher T Bever
May 12, 2006·Neurological Research·Robert N Schwendimann
Sep 1, 2002·Expert Review of Neurotherapeutics·Maria Pia Amato, Valentina Zipoli
Apr 22, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J Iriarte, de Castro P
Oct 19, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Arun V Krishnan, Matthew C Kiernan
May 21, 1999·Multiple Sclerosis : Clinical and Laboratory Research·P F Smith, C L Darlington
Apr 25, 2000·Multiple Sclerosis : Clinical and Laboratory Research·J IriarteP Castro
May 12, 2004·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·S Goulay-DufaÿD Pradeau
Dec 18, 2013·The Cochrane Database of Systematic Reviews·Dian HeHongyu Zhou
Nov 1, 2001·The Cochrane Database of Systematic Reviews·A SolariC Taus
Dec 22, 1999·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·K J Smith, W I McDonald
Jan 10, 2012·Expert Opinion on Pharmacotherapy·Maria Pia Amato, Emilio Portaccio
Oct 4, 2006·The Journal of Pharmacology and Experimental Therapeutics·Thomas W ClaydonDavid Fedida
Sep 18, 2002·Neurorehabilitation and Neural Repair·Randall T Schapiro
Jun 14, 2003·The Cochrane Database of Systematic Reviews·A SolariC Taus
Mar 3, 2021·Contemporary Clinical Trials·Charles H BombardierGeorge H Kraft

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.